Serotonin transporters in the midbrain of Parkinson's disease patients: A study with 123I-β-CIT SPECT

Journal of Nuclear Medicine

Volumn 44, Issue 6, 2003, Pages 870-876

  Sang, Eun Kim ^a   Joon, Young Choi ^a   Yearn, Seong Choe ^a   Choi, Yong ^a   Won, Yong Lee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

2 carbomethoxy 3 (4 123iodophenyl)tropane; Dopamine transporter; Midbrain; Parkinson's disease; Serotonin transporter; SPECT

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; DOPAMINE TRANSPORTER; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; COCAINE; DIAGNOSTIC AGENT; DOPAMINE; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOACTIVE IODINE; SEROTONIN; SLC6A4 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BINDING; DRUG ELIMINATION; HUMAN; MESENCEPHALON; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE; UPREGULATION; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; COCAINE; DOPAMINE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; METABOLIC CLEARANCE RATE; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0038162372     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hornykiewicz O. Dopamine and brain function. Pharmacol Rev. 1966;18:925-964.
2. Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
3. Agid Y, Javoy-Agid F, Ruberg M Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London, U K.: Butterworth; 1987:166-230
4. Halliday GM, Blumberg PC, Cotton RG, Blessing WW, Geffen LB. Loss of brain stem serotonin- and substance P-containmg neurons in Parkinson's disease. Brain Res. 1990;510:104-107.
5. Jellinger K New developments in the pathology of Parkinson's disease. Adv Neurol. 1990;53:1-16.
6. Bernheimer H, Birkmayer W, Hornykiewicz O. Distribution of 5-hydroxytryptamines (serotonin) in brain of men and its behavior in patients with Parkinson-syndrome [in German]. Klin Wochenschr. 1961;39:1056-1059.
7. Birkmayer W, Riederer P Serotonin and extrapyramidal disorders. In: Boullin DJ. ed. Serotonin in Mental Abnormalities. Chichester, U.K.: John Wiley; 1978: 273-302.
8. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983;275:321-328.
9. 3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol. 1985;117: 71-80.
10. 3H-paroxetine binding sites in putamen. Neurology. 1986;36: 556-560.
11. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol. 1987;22:229-236.
12. 3H]citalopram. Neuroscience. 1993;54:691-699.
13. Scheffel U, Dannals RF, Suehiro M, et al. Development of PET/SPECT ligands for the serotonin transporter. NIDA Res Monogr. 1994;138:111-130.
14. 123I]-23-Carbomethoxy- 3β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
15. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse. 1992;12:27-36.
16. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates Synapse. 1993,13:295-309.
17. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal transporters in Parkinson's disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
18. Seibyl JP, Wallace E, Smith EO, et al. Whole-body biodistribution, radiation absorbed dose, and brain SPECT imaging with iodine-123-β-CIT in healthy human subjects. J Nucl Med. 1994;35:764-770.
19. Pirker W, Asenbaum S, Kasper S, et al β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm. 1995;100:247-256.
20. Gjedde A, Wong DF. Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HN Jr, eds. Quantitative imaging: Neuroreceptors, Neurotransmitters, and Enzymes New York, NY: Raven Press; 1990:51-79.
21. Zea-Ponce Y, Baldwin RM, Laruelle M, Wang S, Neumeyer JL. Innis RB. Simplified multidose preparation of iodine-123-β-CIT: a marker for dopamine transporters J Nucl Med. 1995;36:525-529.
22. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M. eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987.153-164.
23. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiarty. 1960;23:56-62.
24. Chang L. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 1987;NS-25:638-643.
25. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258-261
26. Nyberg S, Farde L, Eriksson L, Halldin C, Erikssun B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology. 1993;110:265-272
27. Ichise M, Ballinger JR, Golan H, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med. 1996,37:513-520.
28. -)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10: 740-747.
29. 11C-raclopride in living human brain: a search for extrastriatal central D2-dopamine receptors by PET Psychopharmacology. 1988;94:471-478.
30. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis J Cereb Blood Flow Metab 1989;9:696-708
31. Levenberg K. A method for the solution of certain problems in least squares. Q Appl Math. 1944;2:164-168.
32. Lassen NA. Neuroreceptor quantitation in vivo by the steady state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab. 1992;12:709-716.
33. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
34. 123I-β-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44.
35. Szabo Z, Preziosi T, Hoehn-Saric R, et al. PET imaging reveals reduced [C-11](+)MeN5652 binding to 5-HT transporters in Parkinson's disease [abstract] Abstr Soc Neurosci. 1996;22:721.
36. 123I β-CIT SPECT [abstract]. J Nucl Med 2000;41(suppl):221P.
37. Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H. Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett. 1993,150: 71-74.
38. Mayeux R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol. 1990;53 163-166.
39. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-dopa therapy Adv Neurol. 1996;69:545-550.
40. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science. 1970;170:76-77.